# US 2024/0390532 A1 · Radioimmunoconjugates targeting grp78 for use in the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390532 A1
- Document ID: US20240390532A1
- Status: Published application
- Kind: A1
- Application number: 18/696,453
- Filed: 2022-09-28
- Published: 2024-11-28
- Earliest claimed: 2021-09-28
- Assignees: Actinium Pharmaceuticals, Inc.
- Applicants: Actinium Pharmaceuticals, Inc.
- Inventors: Dale L. LUDWIG; Eileen GEOGHEGAN; Helen KOTANIDES; Sandesh SETH
- Web page: https://patentgrep.com/patent/US20240390532A1

## CPC

- A61K 51/1096: {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}
- C07K 16/18: against material from animals or humans
- A61K 39/39533: {against materials from animals}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- A61K 51/1093: {conjugates with carriers being antibodies}
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 2039/505: {comprising antibodies}
- A61K 2121/00: Preparations for use in therapy
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for treating cancers and precancerous conditions by administering an effective amount of a radiolabeled agent that targets cell surface GRP78, alone or in combination with other therapies, are provided. The radiolabeled GRP78 targeting agent delivers radiation to cells that externally present GRP78, such as tumor cells, depleting those cells and neighboring malignant cells to effect overall tumor reduction. Radiation delivered by the radiolabeled GRP78 targeting agent itself increases the cell surface expression of GRP78, leading to a feed-forward mechanism that drives further accumulation of the GRP78 targeting agent at target lesions to enhance its therapeutic effect.

## Claims

### Claim at position 1

1-12. (canceled)

### Claim 13

A method for treating a cancer or precancerous disorder in a mammalian subject, comprising:
administering to the mammalian subject in need of treatment for a cancer or precancerous disorder a therapeutically effective amount of a radiolabeled GRP78 targeting agent,
wherein the radiolabeled GRP78 targeting agent comprises at least one radiolabel selected from 131I, 125I, 123I, 90Y, 177Lu, 186Re, 188Re, 89Sr, 153Sm, 32P, 225Ac, 213Po, 211At, 212Bi, 213Bi 223Ra, 227Th, 149Tb, 161Tb, 47Sc, 67Cu, 134Ce, 137Cs, 212Pb, and 103Pd.

### Claim 14 (depends on 13)

The method of claim 13, wherein the radiolabeled GRP78 targeting agent comprises at least one radiolabel selected from 90Y, 177Lu, 186Re, 225Ac, 211At, 212Bi, 213Bi, 227Th, 149Tb, 161Tb, 47Sc, 67Cu, 134Ce, 137Cs, and 212Pb.

### Claim 15 (depends on 13)

The method of claim 13, wherein the cancer or precancerous disorder is a hematological cancer or precancerous disorder.

### Claim 16 (depends on 13)

The method of claim 13, wherein the cancer or precancerous disorder is a solid cancer or solid precancerous disorder.

### Claim 17 (depends on 16)

The method of claim 16, wherein the solid cancer or solid precancerous disorder comprises a sarcoma, a carcinoma, breast cancer, TNBC, gastric cancer, bladder cancer, cervical cancer, endometrial cancer, skin cancer, melanoma, bone cancer, osteosarcoma, stomach cancer, testicular cancer, esophageal cancer, bronchioloalveolar cancer, prostate cancer, colorectal cancer, ovarian cancer, cervical epidermoid cancer, pancreatic cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, liver cancer, hepatocellular carcinoma, cholangiocarcinoma, renal cancer, renal cell carcinoma, or head and neck cancer.

### Claim 18 (depends on 13)

The method of claim 13, wherein the therapeutically effective amount of the radiolabeled GRP78 targeting agent comprises an amount effective to increase cell surface exposed GRP78 on cancer cells.

### Claim 19 (depends on 13)

The method of claim 13, wherein the radiolabeled GRP78 targeting agent comprises a radiolabeled monoclonal antibody or a radiolabeled GRP78-binding fragment of a monoclonal antibody.

### Claim 20 (depends on 13)

The method of claim 13, wherein the radiolabeled GRP78 targeting agent comprises a radiolabeled GRP78 binding peptide.

### Claim 21 (depends on 13)

The method of claim 13, wherein the radiolabeled GRP78 targeting agent is an 225Ac-labeled GRP78 targeting agent, and the therapeutically effective amount of the 225Ac-labeled GRP78 targeting agent comprises:
a protein or peptide dose of less than 3 mg/kg subject body weight, or from 0.001 mg/subject body weight to 3.0 mg/kg subject body weight, or from 0.005 mg/kg subject body weight to 2.0 mg/kg subject body weight, or from 0.01 mg/kg subject body weight to 1 mg/kg subject body weight, or from 0.1 mg/kg subject body weight to 0.6 mg/kg subject body weight, or 0.3 mg/kg subject body weight, or 0.4 mg/kg subject body weight, or 0.5 mg/kg subject body weight, or 0.6 mg/kg subject body weight; and
a radiation dose of 0.1 to 50 μCi/kg subject body weight, or 0.1 to 5 μCi/kg subject body weight, or 5 to 20 μCi/kg subject body weight.

### Claim 22 (depends on 13)

The method of claim 13, wherein the radiolabeled GRP78 targeting agent is an 225Ac-labeled GRP78 targeting agent, and the therapeutically effective amount of the 225Ac-labeled GRP78 targeting agent comprises:
a protein or peptide dose of less than 3 mg/kg subject body weight, or from 0.001 mg/kg patient weight to 3.0 mg/kg subject body weight, or from 0.005 mg/kg subject body weight to 2.0 mg/kg subject body weight, or from 0.01 mg/kg subject body weight to 1 mg/kg subject body weight, or from 0.1 mg/kg subject body weight to 0.6 mg/kg subject body weight, or 0.3 mg/kg subject body weight, or 0.4 mg/kg subject body weight, or 0.5 mg/kg subject body weight, or 0.6 mg/kg subject body weight; and
a radiation dose of 2 μCi to 2 mCi, or 2 μCi to 250 μCi, or 75 μCi to 400 μCi.

### Claim at position 12

23-40. (canceled)

### Claim 41 (depends on 13)

The method of claim 13, wherein the radiolabeled GRP78 targeting agent comprises an antibody or GRP78-binding antibody fragment comprising:
heavy chain CDR regions VHCDR1, VHCDR2, VHCDR3, having the amino acid sequences set forth in SEQ ID NO:203, SEQ ID NO:204, and SEQ ID NO:205, respectively, and
light chain CDR regions VLCDR1, VLCDR2, and VLCDR3 having the amino acid sequences set forth in SEQ ID NO:206, SEQ ID NO:207, and SEQ ID NO:208, respectively.

### Claim 42 (depends on 14)

The method of claim 14, wherein the cancer or precancerous disorder is a hematological cancer or precancerous disorder.

### Claim 43 (depends on 14)

The method of claim 14, wherein the cancer or precancerous disorder is a solid cancer or solid precancerous disorder.

### Claim 44 (depends on 43)

The method of claim 43, wherein the solid cancer or solid precancerous disorder comprises a sarcoma, a carcinoma, breast cancer, TNBC, gastric cancer, bladder cancer, cervical cancer, endometrial cancer, skin cancer, melanoma, bone cancer, osteosarcoma, stomach cancer, testicular cancer, esophageal cancer, bronchioloalveolar cancer, prostate cancer, colorectal cancer, ovarian cancer, cervical epidermoid cancer, pancreatic cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, liver cancer, hepatocellular carcinoma, cholangiocarcinoma, renal cancer, renal cell carcinoma, or head and neck cancer.

### Claim 45 (depends on 14)

The method of claim 14, wherein the therapeutically effective amount of the radiolabeled GRP78 targeting agent comprises an amount effective to increase cell surface exposed GRP78 on cancer cells.

### Claim 46 (depends on 14)

The method of claim 14, wherein the radiolabeled GRP78 targeting agent comprises a radiolabeled monoclonal antibody or a radiolabeled GRP78-binding fragment of a monoclonal antibody.

### Claim 47 (depends on 14)

The method of claim 14, wherein the radiolabeled GRP78 targeting agent comprises a radiolabeled GRP78 binding peptide.

### Claim 48 (depends on 19)

The method of claim 19, wherein the radiolabeled GRP78 targeting agent is an 225Ac-labeled GRP78 targeting agent, and the therapeutically effective amount of the 225Ac-labeled GRP78 targeting agent comprises:
a protein or peptide dose of less than 3 mg/kg subject body weight, or from 0.001 mg/subject body weight to 3.0 mg/kg subject body weight, or from 0.005 mg/kg subject body weight to 2.0 mg/kg subject body weight, or from 0.01 mg/kg subject body weight to 1 mg/kg subject body weight, or from 0.1 mg/kg subject body weight to 0.6 mg/kg subject body weight, or 0.3 mg/kg subject body weight, or 0.4 mg/kg subject body weight, or 0.5 mg/kg subject body weight, or 0.6 mg/kg subject body weight; and
a radiation dose of 0.1 to 50 μCi/kg subject body weight, or 0.1 to 5 μCi/kg subject body weight, or 5 to 20 μCi/kg subject body weight.

### Claim 49 (depends on 19)

The method of claim 19, wherein the radiolabeled GRP78 targeting agent is an 225Ac-labeled GRP78 targeting agent, and the therapeutically effective amount of the 225Ac-labeled GRP78 targeting agent comprises:
a protein or peptide dose of less than 3 mg/kg subject body weight, or from 0.001 mg/kg patient weight to 3.0 mg/kg subject body weight, or from 0.005 mg/kg subject body weight to 2.0 mg/kg subject body weight, or from 0.01 mg/kg subject body weight to 1 mg/kg subject body weight, or from 0.1 mg/kg subject body weight to 0.6 mg/kg subject body weight, or 0.3 mg/kg subject body weight, or 0.4 mg/kg subject body weight, or 0.5 mg/kg subject body weight, or 0.6 mg/kg subject body weight; and
a radiation dose of 2 μCi to 2 mCi, or 2 μCi to 250 μCi, or 75 μCi to 400 μCi.

### Claim 50 (depends on 20)

The method of claim 20, wherein the radiolabeled GRP78 targeting agent is an 225Ac-labeled GRP78 targeting agent, and the therapeutically effective amount of the 225Ac-labeled GRP78 targeting agent comprises:
a protein or peptide dose of less than 3 mg/kg subject body weight, or from 0.001 mg/subject body weight to 3.0 mg/kg subject body weight, or from 0.005 mg/kg subject body weight to 2.0 mg/kg subject body weight, or from 0.01 mg/kg subject body weight to 1 mg/kg subject body weight, or from 0.1 mg/kg subject body weight to 0.6 mg/kg subject body weight, or 0.3 mg/kg subject body weight, or 0.4 mg/kg subject body weight, or 0.5 mg/kg subject body weight, or 0.6 mg/kg subject body weight; and
a radiation dose of 0.1 to 50 μCi/kg subject body weight, or 0.1 to 5 μCi/kg subject body weight, or 5 to 20 μCi/kg subject body weight.

### Claim 51 (depends on 20)

The method of claim 20, wherein the radiolabeled GRP78 targeting agent is an 225Ac-labeled GRP78 targeting agent, and the therapeutically effective amount of the 225Ac-labeled GRP78 targeting agent comprises:
a protein or peptide dose of less than 3 mg/kg subject body weight, or from 0.001 mg/kg patient weight to 3.0 mg/kg subject body weight, or from 0.005 mg/kg subject body weight to 2.0 mg/kg subject body weight, or from 0.01 mg/kg subject body weight to 1 mg/kg subject body weight, or from 0.1 mg/kg subject body weight to 0.6 mg/kg subject body weight, or 0.3 mg/kg subject body weight, or 0.4 mg/kg subject body weight, or 0.5 mg/kg subject body weight, or 0.6 mg/kg subject body weight; and
a radiation dose of 2 μCi to 2 mCi, or 2 μCi to 250 μCi, or 75 μCi to 400 μCi.

### Claim 52 (depends on 41)

The method of claim 41, wherein the radiolabeled GRP78 targeting agent is an 225Ac-labeled GRP78 targeting agent, and the therapeutically effective amount of the 225Ac-labeled GRP78 targeting agent comprises:
a protein or peptide dose of less than 3 mg/kg subject body weight, or from 0.001 mg/subject body weight to 3.0 mg/kg subject body weight, or from 0.005 mg/kg subject body weight to 2.0 mg/kg subject body weight, or from 0.01 mg/kg subject body weight to 1 mg/kg subject body weight, or from 0.1 mg/kg subject body weight to 0.6 mg/kg subject body weight, or 0.3 mg/kg subject body weight, or 0.4 mg/kg subject body weight, or 0.5 mg/kg subject body weight, or 0.6 mg/kg subject body weight; and
a radiation dose of 0.1 to 50 μCi/kg subject body weight, or 0.1 to 5 μCi/kg subject body weight, or 5 to 20 μCi/kg subject body weight.

### Claim 53 (depends on 41)

The method of claim 41, wherein the radiolabeled GRP78 targeting agent is an 225Ac-labeled GRP78 targeting agent, and the therapeutically effective amount of the 225Ac-labeled GRP78 targeting agent comprises:
a protein or peptide dose of less than 3 mg/kg subject body weight, or from 0.001 mg/kg patient weight to 3.0 mg/kg subject body weight, or from 0.005 mg/kg subject body weight to 2.0 mg/kg subject body weight, or from 0.01 mg/kg subject body weight to 1 mg/kg subject body weight, or from 0.1 mg/kg subject body weight to 0.6 mg/kg subject body weight, or 0.3 mg/kg subject body weight, or 0.4 mg/kg subject body weight, or 0.5 mg/kg subject body weight, or 0.6 mg/kg subject body weight; and
a radiation dose of 2 μCi to 2 mCi, or 2 μCi to 250 μCi, or 75 μCi to 400 μCi.
